JPMorgan 24th Annual Healthcare Conference.
Dalziel
Chris
C
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. christopher.dalziel@thomson.com
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002762:Cholecalciferol / Q000031:analogs & derivatives / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003695:Delivery of Health Care; D004345:Drug Industry; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy; D014570:Urologic Diseases / Q000188:drug therapy; D014815:Vitamins / Q000627:therapeutic use; D047090:beta-Lactams / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D018841:HSP90 Heat-Shock Proteins; D014815:Vitamins; D047090:beta-Lactams; D002762:Cholecalciferol; C107057:fropenem